IXICO PLC, specializing in neuroscience imaging and biomarker analytics for clinical drug trials, forecasts at least 15% revenue growth for the full year. The company raised £10 million in April to accelerate its 'TechBio' strategy, integrating its AI-driven IXI platform with third-party clinical trial systems and healthcare providers. Interim results showed a 23% revenue increase to £3.9 million and a 38% rise in the order book to £18.1 million, signaling strong future revenue visibility. Key developments include a partnership with Medidata, expansion into US and Asia markets, and advances in biomarkers for Alzheimer's and Parkinson's diseases, positioning IXICO for sustainable growth.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
Empire Metals Ltd has signed a definitive agreement to sell its 75% stake in the Eclipse Mining Lease near Kalgoorlie, Western Australia, for A$750,000. The sale includes a non-refundable deposit of A$50,000 already received, with the remaining A$700...
Dr Martens reported a 61% increase in adjusted pre-tax profit to £55 million for the year ending March 29, despite a 2.9% revenue decline to £764.9 million. The company improved gross margins to 66.2% by reducing discounting and focusing on higher-qu...
Coiled Therapeutics, a clinical-stage oncology company, has begun trading on the US OTCQB Venture Market under the ticker COTXF, allowing US investors to buy shares in dollars during US market hours. This move aims to improve liquidity and broaden it...
Currys PLC expects its annual adjusted pre-tax profit to reach about £191 million, surpassing previous guidance due to strong sales in the UK and Nordic markets. Group like-for-like sales increased 4% for the full year, with the Nordics showing parti...
